Back to Authors

Gian, Richard Kinh

https://orcid.org/0000-0002-6554-0310

A5058483454 | I1334819555

Mayo Clinic

Memorial Sloan Kettering Cancer Center

Citations 4

Factors Associated With Aborted Whipple Procedures for Periampullary Carcinoma: A Multicenter Case-Control Study by the SAR Pancreatic Ductal Adenocarcinoma Disease Focus Panel

American Journal of Roentgenology | March 5, 2025 | Volume: 224 | Issue: 5 | Pages: No page available

10.2214/ajr.24.32160 | PMID 40042924

Updates on LI‐RADS Treatment Response Criteria for Hepatocellular Carcinoma: Focusing on MRI

Journal of Magnetic Resonance Imaging | March 6, 2023 | Volume: 57 | Issue: 6 | Pages: 1641-1654

10.1002/jmri.28659 | PMID 36872608

As the incidence of hepatocellular carcinoma (HCC) and subsequent treatments with liver‐directed therapies rise, the complexity of assessing lesion response has also increased. The Liver Imaging Reporting and Data Systems (LI‐RADS) treatment response algorithm (LI‐RADS TRA) was created to standardize the assessment of response after locoregional therapy (LRT) on contrast‐enhanced CT or MRI. Originally created based on expert opinion, these guidelines are currently undergoing revision based on emerging evidence. While many studies support the use of LR‐TRA for evaluation of HCC response after thermal ablation and intra‐arterial embolic therapy, data suggest a need for refinements to improve assessment after radiation therapy. In this manuscript, we review expected MR imaging findings after different forms of LRT, clarify how to apply the current LI‐RADS TRA by type of LRT, explore emerging literature on LI‐RADS TRA, and highlight future updates to the algorithm.Evidence Level3.Technical EfficacyStage 2.
Precision Management of a Patient With Dihydropyrimidine Dehydrogenase Deficiency and Liver-Predominant Metastatic Rectal Cancer Using Hepatic Arterial Floxuridine

JCO Precision Oncology | February 27, 2023 | Volume: No volume available | Issue: 7 | Pages: No page available

10.1200/po.22.00442 | PMID 36848609

A multicenter pilot study of nivolumab (NIVO) with drug eluting bead transarterial chemoembolization (deb-TACE) in patients (pts) with liver limited hepatocellular carcinoma (HCC).

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: TPS4146-TPS4146

10.1200/jco.2018.36.15_suppl.tps4146